APA

Thapa P., Ranade R., Ostwal V., Shrikhande S. V., Goel M. & Basu S. (20170302). Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. : Nuclear medicine communications.

Chicago

Thapa Pradeep, Ranade Rohit, Ostwal Vikas, Shrikhande Shailesh V, Goel Mahesh and Basu Sandip. 20170302. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. : Nuclear medicine communications.

Harvard

Thapa P., Ranade R., Ostwal V., Shrikhande S. V., Goel M. and Basu S. (20170302). Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. : Nuclear medicine communications.

MLA

Thapa Pradeep, Ranade Rohit, Ostwal Vikas, Shrikhande Shailesh V, Goel Mahesh and Basu Sandip. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. : Nuclear medicine communications. 20170302.